中华行为医学与脑科学杂志
中華行為醫學與腦科學雜誌
중화행위의학여뇌과학잡지
CHINESE JOURNAL OF BEHAVIORAL MEDICINE AND BRAIN SCIENCE
2012年
11期
997-999
,共3页
王俊清%许崇涛%江丽云%温碧兰
王俊清%許崇濤%江麗雲%溫碧蘭
왕준청%허숭도%강려운%온벽란
精神分裂症%多导睡眠图%奥氮平%体质量%睡眠呼吸障碍
精神分裂癥%多導睡眠圖%奧氮平%體質量%睡眠呼吸障礙
정신분렬증%다도수면도%오담평%체질량%수면호흡장애
First-episode schizophrenics%Polysomnography%Olanzapine%Body weight%Sleep-breathing disorder
目的 探索首次发病的精神分裂症患者多导睡眠图(Polysomnography,PSG)特征以及奥氮平治疗对体质量、睡眠呼吸的影响.方法 对36例首发精神分裂症患者和33名正常对照进行整夜PSG监测,比较两组PSG的差异以及奥氮平治疗前后患者组体质量、睡眠呼吸的差异.结果 治疗前与对照组比较,患者组睡眠潜伏期延长[(83.64±10.62) min,(29.41±10.05) min],总睡眠时间减少[(286.43±17.04) min,(343.66±16.38) min],睡眠效率下降[(65.73±11.47)％,(86.13±8.15)％],睡眠期觉醒时间和微觉醒次数明显增多[(65.70±10.33) min,(25.93±9.60) min；(38.26±6.88),(14.40±2.72)]；N1期睡眠增加[(87.43±11.35) min,(36.55±6.40) min],N2期、N3期睡眠减少[(100.53±10.42) min,(143.35±13.52)min；(49.83±7.51) min,(87.52±9.74)min],上述组间差异有统计学意义(P＜0.05)；治疗后与对照组比较,患者组体质量指数[(30.67±3.41),(24.66±4.03)]、微觉醒次数[(23.52±3.63),(14.40±2.72)]、低通气指数[(8.47±0.52),(3.64±0.48)]差异有统计学意义(均P＜0.05)；患者组自身前后比较,体质量指数增加(P＜0.05),睡眠连续性和结构指标改善,差异有统计学意义(均P＜0.05).结论 首发精神分裂症患者有睡眠连续性和睡眠结构两方面异常；奥氮平治疗能显著改善患者睡眠质量,但长期治疗有可能导致体质量增加及睡眠呼吸异常.
目的 探索首次髮病的精神分裂癥患者多導睡眠圖(Polysomnography,PSG)特徵以及奧氮平治療對體質量、睡眠呼吸的影響.方法 對36例首髮精神分裂癥患者和33名正常對照進行整夜PSG鑑測,比較兩組PSG的差異以及奧氮平治療前後患者組體質量、睡眠呼吸的差異.結果 治療前與對照組比較,患者組睡眠潛伏期延長[(83.64±10.62) min,(29.41±10.05) min],總睡眠時間減少[(286.43±17.04) min,(343.66±16.38) min],睡眠效率下降[(65.73±11.47)％,(86.13±8.15)％],睡眠期覺醒時間和微覺醒次數明顯增多[(65.70±10.33) min,(25.93±9.60) min；(38.26±6.88),(14.40±2.72)]；N1期睡眠增加[(87.43±11.35) min,(36.55±6.40) min],N2期、N3期睡眠減少[(100.53±10.42) min,(143.35±13.52)min；(49.83±7.51) min,(87.52±9.74)min],上述組間差異有統計學意義(P＜0.05)；治療後與對照組比較,患者組體質量指數[(30.67±3.41),(24.66±4.03)]、微覺醒次數[(23.52±3.63),(14.40±2.72)]、低通氣指數[(8.47±0.52),(3.64±0.48)]差異有統計學意義(均P＜0.05)；患者組自身前後比較,體質量指數增加(P＜0.05),睡眠連續性和結構指標改善,差異有統計學意義(均P＜0.05).結論 首髮精神分裂癥患者有睡眠連續性和睡眠結構兩方麵異常；奧氮平治療能顯著改善患者睡眠質量,但長期治療有可能導緻體質量增加及睡眠呼吸異常.
목적 탐색수차발병적정신분렬증환자다도수면도(Polysomnography,PSG)특정이급오담평치료대체질량、수면호흡적영향.방법 대36례수발정신분렬증환자화33명정상대조진행정야PSG감측,비교량조PSG적차이이급오담평치료전후환자조체질량、수면호흡적차이.결과 치료전여대조조비교,환자조수면잠복기연장[(83.64±10.62) min,(29.41±10.05) min],총수면시간감소[(286.43±17.04) min,(343.66±16.38) min],수면효솔하강[(65.73±11.47)％,(86.13±8.15)％],수면기각성시간화미각성차수명현증다[(65.70±10.33) min,(25.93±9.60) min；(38.26±6.88),(14.40±2.72)]；N1기수면증가[(87.43±11.35) min,(36.55±6.40) min],N2기、N3기수면감소[(100.53±10.42) min,(143.35±13.52)min；(49.83±7.51) min,(87.52±9.74)min],상술조간차이유통계학의의(P＜0.05)；치료후여대조조비교,환자조체질량지수[(30.67±3.41),(24.66±4.03)]、미각성차수[(23.52±3.63),(14.40±2.72)]、저통기지수[(8.47±0.52),(3.64±0.48)]차이유통계학의의(균P＜0.05)；환자조자신전후비교,체질량지수증가(P＜0.05),수면련속성화결구지표개선,차이유통계학의의(균P＜0.05).결론 수발정신분렬증환자유수면련속성화수면결구량방면이상；오담평치료능현저개선환자수면질량,단장기치료유가능도치체질량증가급수면호흡이상.
Objective To explore the sleep characteristics in first-episode schizophrenics and the effects of olanzapine on body weight and sleep-breathing disorder.Methods 36 first-episode schizophrenics (patient group) and 33 normal controls (control group) were tested with polysomnography(PSG),and compared the difference of PSG,sleep-breathing index and body mass index(BMI) before and after treatment in patient group.Results Before treatment,compared with control group,the patient group had significantly prolonged sleep latency((83.64± 10.62) min vs (29.41 ± 10.05) min),shortened total sleep time ((286.43 ± 17.04) min vs (343.66 ± 16.38)min),decreased sleep efficiency((65.73 ±11.47) vs (86.13 ± 8.15)),increased awake time and arousal number((65.70 ± 10.33) min vs (25.93 ± 9.60) min ; (38.26 ± 6.88) vs (14.40 ± 2.72)) in sleep continuity ; and increased N1 stage ((87.43 ± 11.35) min vs (36.55 ± 6.40) min),decreased N2,N3 stage ((100.53 ± 10.42)minvs (143.35±13.52)min;(49.83±7.51)minvs (87.52±9.74)min) in sleep structure (P ＜ 0.05).After treatment,sleep continuity and sleep structure in patient group were improved,compared with control group,only BMI,arousal index and hypopnea index had statistic difference (P ＜ 0.05).Conclusion The first-episode schizophrenics have both sleep continuity and sleep structure deficits.Although olanzapine treatment can improve sleep quality,long-term use of it may cause overweight and sleep-breathing disorder.
